KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies.
KIYATEC utilizes the patient’s own living tumor cells to create functional 3D models to test a battery of cancer therapies. Its 3DKUBE technology platform conveniently and cost-effectively incorporates perfusion flow, accommodates all scaffold materials, allows in situ imaging, models complex human biology using segregated cell co‐culture, and is a single-use disposable. 3DKUBE cell‐based assays leverage these features to create better in vitro prediction of complex biochemical responses in humans, with a focus on the evaluation of drug toxicity and efficacy prior to use in human clinical trials.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 12, 2022 | Series C | $18M | 4 | Bruker | — | Detail |
Apr 30, 2021 | Series Unknown | $2.50M | 2 | Seae Ventures | — | Detail |
May 1, 2019 | Series B | $3M | 2 | VentureSouth | — | Detail |
Dec 15, 2017 | Convertable Note | $2.20M | 1 | — | — | Detail |
Dec 15, 2015 | Series B | $2.85M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bruker | Yes | Series C |
NMT Capital | Yes | Series A |
LabCorp | — | Series C |
Seae Ventures | — | Series C |
VentureSouth | — | Series C |
Upstate Carolina Angel Network | — | Series A |